Sixty-two patients with moderately severe anxiety symptoms were treated in a double bline 3-week trial with either oxprenolol, diazepam or placebo. The Hamilton Anxiety Scale and a Target symptom improvement score were the main measures of change used. All treatment groups significantly improved in
An algorithm for evaluating the ethics of a placebo-controlled trial
โ Scribed by Robert J. Amdur; C.J. Biddle
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 320 KB
- Volume
- 96
- Category
- Article
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.1026
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
The purpose of this article is to clarify the decision points that are important to consider when evaluating the ethics of a placeboโcontrolled trial. The ethical requirements for research involving human subjects are reviewed, and the rationale for and potential problems with concomitant placebo control are explained. A series of case discussions are used to illustrate each decision point. The critical decision points in the evaluation of the ethics of a placeboโcontrolled trial are as follows: (i) Is placebo being used in place of standard therapy? (ii) Is standard therapy likely to be effective? (iii) Is the toxicity of standard therapy such that patients routinely refuse this treatment? (iv) Could the use of placebo result in severe suffering or irreversible harm? (v) Is the variability in the placebo response such that it is reasonable to consider other options for the control group? (vi) Would a reasonable person with an average degree of altruism and risk aversiveness agree to participate in this study? The algorithm presented in this article gives researchers and research monitors (such as Institutional Review Board members) the tools they need to evaluate the ethics of a study that uses concomitant placebo control. ยฉ 2001 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome. Methods: There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Touret